MPN & Myelofibrosis Education
Myelofibrosis and myeloproliferative neoplasms represent one of the largest hematology market segments, with JAK inhibitor sequencing, novel combination approaches, and transplant timing creating complex treatment decisions. Knowledge Med sessions help physicians work through these challenges using interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing myeloproliferative neoplasms & myelofibrosis face evolving treatment decisions that interactive, independently reviewed education can help address.
- Selecting among JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) based on patient profile
- Managing JAK inhibitor failure and sequencing second-line therapy
- Addressing anemia in myelofibrosis — momelotinib, luspatercept, and transfusion strategies
- Identifying and timing transplant candidates in intermediate/high-risk disease
What Sessions Cover
Knowledge Med MPN / MF sessions use interactive case simulations to address these topics and more.
- Risk-stratified first-line JAK inhibitor selection in myelofibrosis
- Managing cytopenias: anemia-directed approaches and combination strategies
- Second-line therapy after ruxolitinib: options and clinical evidence
- Polycythemia vera and essential thrombocythemia: evolving management
Interactive MPN / MF Sessions
Case Simulations
Work through realistic myeloproliferative neoplasms & myelofibrosis patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key MPN / MF clinical takeaways.
More Hematologic Malignancy Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Chronic Lymphocytic Leukemia
CLL / SLL — First-line therapy selection in CLL: BTK inhibitors vs venetoclax combinations
Diffuse Large B-Cell Lymphoma
DLBCL — Frontline DLBCL: pola-R-CHP and risk-adapted strategies
Multiple Myeloma
Frontline induction: triplet vs quadruplet therapy and transplant decisions
Acute Myeloid Leukemia
AML — Molecular-guided frontline therapy selection in AML
Join a MPN / MF Session
Third-party, non-promotional myeloproliferative neoplasms & myelofibrosis education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session